Head-to-head real-world study reports overall survival advantage with apalutamide compared with darolutamide in metastatic castration-sensitive prostate cancer

A retrospective real-world analysis announced by Johnson & Johnson and presented at the 36th Annual International Prostate Cancer Update reports higher overall survival outcomes for apalutamide compared with darolutamide in metastatic castration-sensitive prostate cancer (mCSPC), based on routine clinical practice data.

The head-to-head, comparative effectiveness analysis reported a statistically significant difference in overall survival between patients with mCSPC treated with apalutamide and those treated with darolutamide, when neither therapy was combined with docetaxel. The findings were presented on February 2, 2026 at the 36th Annual International Prostate Cancer Update, where the analysis was selected as a top abstract.

Prostate cancer remains a major clinical burden in the US, with around 330,000 new diagnoses each year and an estimated 36,000 deaths projected in 2026. Given high-risk disease and ongoing recurrence despite treatment advances, comparative real-world evidence (RWE) may complement randomized trial data when informing treatment selection for advanced disease.

According to the findings, patients initiating apalutamide without docetaxel experienced a 51% reduction in the risk of death over 24 months compared with patients initiating darolutamide without docetaxel. The reported hazard ratio for overall survival was 0.49 (95% confidence interval 0.30–0.83; P=0.007). Johnson & Johnson stated that this analysis represents the first real-world head-to-head comparison of overall survival outcomes between these two androgen receptor inhibitors, without the use of docetaxel, in mCSPC.

The retrospective study was designed to align with US Food and Drug Administration (FDA) guidance on RWE. It incorporated a pre-specified protocol, a pre-specified primary endpoint of overall survival, power calculations, and propensity score methods. Inverse probability of treatment weighting (IPTW) was used to balance baseline patient characteristics between treatment groups and reduce bias from measured confounders.

Patients were identified from linked clinical data from private, community-based urology practices and US claims data from the Komodo Research Database, reflecting routine clinical practice. Eligible patients initiated treatment with apalutamide or darolutamide without docetaxel between August 2022 and June 2025. In total, 1460 patients treated with apalutamide and 287 treated with darolutamide met the study inclusion criteria. The analysis was intended to provide comparative evidence in the absence of prospective head-to-head trials, which are considered difficult to conduct in this setting.

“These real-world data show the survival benefit of apalutamide versus darolutamide in patients with mCSPC without the concurrent use of docetaxel,”

said Mehmet Bilen, Director of the Genitourinary Medical Oncology Program at the Winship Cancer Institute of Emory University. He added that the study “utilized large contemporary datasets using rigorous methodology to support clinical decision-making in the absence of prospective head-to-head studies that are likely impractical to conduct.”

The findings add to existing evidence supporting apalutamide in advanced prostate cancer. Previous real-world analyses and the Phase 3 TITAN trial have shown that apalutamide, when used in combination with androgen deprivation therapy (ADT), is associated with rapid and deep declines in prostate-specific antigen levels, which have been linked to improved survival outcomes. In the current real-world study, 92.1% of patients treated with apalutamide were alive at 24 months, broadly consistent with TITAN results.

Mahadi Baig, Vice President of US Medical Affairs at Johnson & Johnson Innovative Medicine, stated:

“Real-world comparisons can provide critical information to support patient care when conducted in a rigorous and methodologically sound manner. We have now seen in repeated real-world examinations the overall survival benefit of apalutamide versus other agents and this head-to-head analysis supports apalutamide being a key standard of care treatment for patients with mCSPC.”

With apalutamide recently selected for the third cycle of Medicare drug price negotiations, this head‑to‑head real‑world survival analysis could further strengthen Johnson & Johnson’s value proposition by demonstrating its comparative effectiveness in routine clinical practice and clarifying its performance relative to a key therapeutic alternative. Given that RWE is expected to play a critical role in CMS’s clinical evaluation of a drug against its therapeutic alternatives, these findings provide timely, decision‑relevant evidence as negotiations proceed.